243 related articles for article (PubMed ID: 21552219)
1. Inadequately met needs.
Nat Biotechnol; 2011 May; 29(5):371. PubMed ID: 21552219
[No Abstract] [Full Text] [Related]
2. Generic drugs: the stalling game.
Consum Rep; 2001 Jul; 66(7):36-40. PubMed ID: 11725791
[TBL] [Abstract][Full Text] [Related]
3. Drug Regulation and Pricing--Can Regulators Influence Affordability?
Eichler HG; Hurts H; Broich K; Rasi G
N Engl J Med; 2016 May; 374(19):1807-9. PubMed ID: 27168431
[No Abstract] [Full Text] [Related]
4. Perspectives. CMS and Wall Street report...
Med Health; 2003 Jan; 57(4):7-8. PubMed ID: 12602066
[No Abstract] [Full Text] [Related]
5. Best buy drugs: many common generics beat brand names.
Consum Rep; 2011 Mar; 76(3):24-7. PubMed ID: 21434454
[No Abstract] [Full Text] [Related]
6. Legal tactics to delay launch of generic drugs cost Europe euro3bn, report says.
Jack A
BMJ; 2008 Dec; 337():a2817. PubMed ID: 19047187
[No Abstract] [Full Text] [Related]
7. [Orphan drugs: drugs for rare diseases].
Schenk M
Dtsch Med Wochenschr; 2010 May; 135(18):p17. PubMed ID: 20455291
[No Abstract] [Full Text] [Related]
8. The new drug war.
Sherrid P
US News World Rep; 2002 Dec; 133(21):41. PubMed ID: 12503485
[No Abstract] [Full Text] [Related]
9. Running short.
Mettner J
Minn Med; 2011 Oct; 94(10):8-10. PubMed ID: 23256277
[No Abstract] [Full Text] [Related]
10. High-cost generic drugs--implications for patients and policymakers.
Alpern JD; Stauffer WM; Kesselheim AS
N Engl J Med; 2014 Nov; 371(20):1859-62. PubMed ID: 25390739
[TBL] [Abstract][Full Text] [Related]
11. Overcoming the obstacles in the pharma/biotech industry: 2008 update.
Graul AI; Revel L; Rosa E; Cruces E
Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298
[TBL] [Abstract][Full Text] [Related]
12. A few specialty drug prices fall--all generics.
Manag Care; 2008 Dec; 17(12):46. PubMed ID: 19127766
[No Abstract] [Full Text] [Related]
13. The calculus of cures.
Kocher R; Roberts B
N Engl J Med; 2014 Apr; 370(16):1473-5. PubMed ID: 24571723
[No Abstract] [Full Text] [Related]
14. Drug costs threaten patent protection.
Cimons M
Nat Med; 2003 Jan; 9(1):9. PubMed ID: 12514706
[No Abstract] [Full Text] [Related]
15. 'Biosimilar' drugs poised to penetrate market.
Ledford H
Nature; 2010 Nov; 468(7320):18-9. PubMed ID: 21048737
[No Abstract] [Full Text] [Related]
16. Therapeutic-class wars--drug promotion in a competitive marketplace.
Kessler DA; Rose JL; Temple RJ; Schapiro R; Griffin JP
N Engl J Med; 1994 Nov; 331(20):1350-3. PubMed ID: 7935706
[No Abstract] [Full Text] [Related]
17. Who's really raising drug prices?
Zagorin A
Time; 1999 Mar; 153(9):46-8. PubMed ID: 10346086
[No Abstract] [Full Text] [Related]
18. Generics industry and doctors nervous over free trade deal.
Burton B
BMJ; 2004 May; 328(7449):1158. PubMed ID: 15142916
[No Abstract] [Full Text] [Related]
19. Survey of pharmacists: impact of the generic drug scandal and implications for marketing generic drugs.
Gupta PB
Health Mark Q; 1996; 13(3):109-20. PubMed ID: 10158484
[TBL] [Abstract][Full Text] [Related]
20. Angst about exclusivity: The potential cost of incentivizing makers of generic drugs.
Chakradhar S; Khamsi R
Nat Med; 2017 Oct; 23(10):1114-1116. PubMed ID: 28985215
[No Abstract] [Full Text] [Related]
[Next] [New Search]
